Congo-Kinshasa: Two Scientists On Their Race to Make a New Ebola Vaccine
Scientists are working to develop a new Ebola vaccine targeting the Bundibugyo strain amid an ongoing outbreak in the Democratic Republic of Congo. The outbreak has resulted in 61 deaths and 359 confirmed cases, complicating efforts due to local challenges. Researchers from the Oxford Vaccine Group are utilizing a viral-vector platform to expedite the vaccine's development and testing process.
- ▪The current Ebola outbreak in the DRC is caused by the Bundibugyo strain, which is not covered by existing vaccines.
- ▪The Oxford Vaccine Group is developing a vaccine candidate using the ChADOx1 platform, similar to the one used for the Oxford-AstraZeneca COVID-19 vaccine.
- ▪They have begun testing the vaccine on small animals and are manufacturing batches for upcoming clinical trials.
AllAfrica files mainly under world. We currently carry 118 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | AllAfrica |
| Canonical URL | https://allafrica.com/stories/202606050004.html |
| Publication time | Fri, 05 Jun 2026 04:09:22 GMT |
| Retrieval time | 2026-06-05T04:15:26.844Z |
| Last seen | 2026-06-05T04:15:26.844Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | in4BYTNA2ZEJ |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
As health workers in the Democratic Republic of Congo (DRC) continue to battle an ongoing Ebola outbreak, scientists around the world are racing to develop a vaccine against the strain of the virus that's causing it. Two approved vaccines exist for Ebola, but they target the Zaire strain of the virus, not the Bundibugyo strain causing the 2026 outbreak - which has so far killed 61 people, with 359 confirmed cases in the DRC and neighbouring Uganda. The outbreak is centred in the Ituri province of northeastern DRC, where conflict, displaced people, a large migrant community and poorly resourced health facilities make stopping the spread particularly challenging.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at AllAfrica.
Discussion
0 commentsMore from AllAfrica
